Report #2845195

Received Jun 16, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: May 16, 2022
Onset: May 16, 2022
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

I took Shingrix first shot on date 11/22/2019 and the second shot on date 05/16/2022; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received on 22-NOV-2019). On 16-MAY-2022, the patient received the 2nd dose of Shingrix. On 16-MAY-2022, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: I took Shingrix first shot on date 11/22/2019 and the second shot on date 05/16/2022). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 06-JUN-2025 This case was reported by a patient via (Shingrix GSK chatbot) interactive digital media. The patient took Shingrix first shot, and the second shot received later than the recommended interval, which led to lengthening of vaccination scheduled.